Sep 30, 2024

Bausch Health Q3 2024 Earnings Report

Bausch Health reported a sixth consecutive quarter of year-over-year growth in both revenue and Adjusted EBITDA, with growth in all segments.

Key Takeaways

Bausch Health announced its third quarter 2024 financial results, achieving a 12% increase in consolidated revenues to $2.51 billion and a 10% rise in Adjusted EBITDA to $909 million. The company also raised its full-year 2024 guidance.

Sixth consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA.

Third quarter consolidated revenues of $2.51 billion, up 12% on a Reported basis.

Consolidated GAAP Net Loss Attributable to Bausch Health Companies Inc. of $85 million.

Consolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. of $909 million, up 10%.

Total Revenue
$2.51B
Previous year: $2.24B
+12.2%
EPS
$1.12
Previous year: $1.03
+8.7%
Adjusted EBITDA
$909M
Previous year: $830M
+9.5%
Gross Profit
$1.53B
Previous year: $1.62B
-5.1%
Cash and Equivalents
$719M
Previous year: $760M
-5.4%
Free Cash Flow
$331M
Previous year: $240M
+37.9%
Total Assets
$26.5B
Previous year: $27.1B
-1.9%

Bausch Health

Bausch Health

Bausch Health Revenue by Segment

Forward Guidance

The Company raised its consolidated full-year Revenue and Adjusted EBITDA guidance:

Revenue & Expenses

Visualization of income flow from segment revenue to net income